Alaunos Reports Preclinical ALN1003 Liver-Weight Signal After Body-Fat Adjustment

Alaunos reports ALN1003-treated mice showed lower liver weight after adjustment for body fat percentage in a 48-day DIO study.Key Highlights:Original SEC Filing: Alaunos Therapeutics, Inc. [ TCRT ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying i…

Alaunos reports ALN1003-treated mice showed lower liver weight after adjustment for body fat percentage in a 48-day DIO study.

Key Highlights:

ANCOVA shows significantly lower liver weight for ALN1003 vs controls (p=0.000005); HC3 robust test confirms (p=0.000015).
Finding suggests lower liver weight is not fully explained by measured body fat percentage in this non-GLP mouse model.
Result is directionally consistent with prior lower liver markers, selected histology, reduced NAS, and 43% lower absolute liver weight in selected samples.
Supports previously reported lower fasting insulin and HOMA-IR (ANCOVA p=0.0006; HC3 p=0.0014) and favorable adipose endocrine biomarkers.
Results are from non-GLP preclinical studies; small sample sizes and other limitations mean findings may not translate to humans.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.